NDAINJECTIONINJECTABLE
Approved
Jan 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
DAUNORUBICIN HYDROCHLORIDE (daunorubicin hydrochloride) by Hikma is clinical pharmacology mechanism of action daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Approved for leukemia, myelodysplastic syndromes, b acute lymphoblastic leukemia. First approved in 1998.
Drug data last refreshed 23h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II…
Worked on DAUNORUBICIN HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.